Technology
4BIO Capital Leads Oversubscribed $28.4 Million Series A Financing Of March Biosciences
(MENAFN - GlobeNewsWire - Nasdaq) March Bio is rapidly advancing its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy, MB-105, in development for the treatment of relapsed and ...
By: menafn
- Oct 23 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS